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What makes a protein immunogenic, particularly for
strong T cell–mediated immunity? To a first approxima-
tion, this determination seems to be made by dendritic cells
(DCs). Immature DCs, as in skin (1–4), lung (5), blood (6,
7), and spleen (7, 8), take up proteins, immune complexes,
microbes, and dying cells. However, in order to use these
antigens to stimulate a T cell response, the DCs must un-
 
dergo a characteristic process of terminal differentiation called
“maturation.” The known stimuli for DC maturation are
 
numerous and include inflammatory cytokines, CD40 ligand
(CD40L), viral and microbial constituents such as double-
stranded RNA and LPS, and certain CpG oligonucleotides.
 
DC Maturation as a Control Point in the Initiation of Immunity
 
Maturation changes DCs in many ways that help explain
their potent immunogenicity. Examples include de novo ex-
pression of T cell costimulatory molecules like CD86 (9, 10);
the capacity to produce IL-12 (11, 12) and resist immunosup-
pression by IL-10 (13); the development of a new repertoire
of chemokine receptors, especially CCR7 (14–17), that guide
entry into lymphatics and migration to the T cell areas (18);
the production of DC survival and stimulatory molecules like
CD40 and TNF-related activation-induced cytokine recep-
tor (TRANCE-R) (19, 20); and a redistribution of MHC
class II molecules from lysosomes to the cell surface (21, 22).
Recently, it has been found (Inaba, K., S. Turley, T. Iyoda,
F. Yamaide, S. Shimoyama, C. Reis e Sousa, R.N. Germain,
J. Mellman, and R.M. Steinman, manuscript submitted for
publication) that immature DCs endocytose proteins into
MHC class II–rich intracellular compartments, but the cells
must also mature to form MHC–peptide complexes there
and to export the complexes to the cell surface together with
B7 costimulators. DC maturation is understandably a key
control point in converting an antigen into an immunogen.
The role for DCs in determining immunogenicity seems
well established, but many are now pursuing their role in
other contexts: immune deviation, i.e., skewing T cells to
the Th2 phenotype; immune regulation, i.e., inducing Tr1
 
cells that make IL-10; and bona fide tolerance, i.e., dele-
tion and anergy. We will comment on the idea that the up-
take of dying cells by immature DCs is critical for the main-
tenance of peripheral tolerance, including the findings in
two papers in this issue. Huang et al. demonstrate that DCs
in afferent lymph carry apoptotic bodies derived from the
intestinal epithelium (23). They present evidence, using an
isoform of intestinal nonspecific esterase, that DCs contin-
ually deliver samples of this tissue to the lymph node. Sau-
ter et al. find that DCs phagocytose apoptotic and necrotic
cell lines, but only the latter cause DCs to mature into
strong stimulators of T cell immunity (24). Both papers
suggest that the uptake of apoptotic cells allows DCs to in-
duce peripheral tolerance to self. We will first outline why
it makes sense for DCs, such potent agents of immunity, to
also ensure tolerance to cell-associated self-antigens that un-
avoidably are present at sites of foreign antigen deposition.
 
The Value of Peripheral Tolerance Induction by DCs
 
Central or thymic tolerance is likely to be mediated by thy-
mic DCs (25, 26), but these DCs may not be able to delete T
cells that react with many self-antigens in peripheral tissues.
Many proteins may not have access to the thymus during de-
velopment, especially antigens that are expressed after the thy-
mus has generated a T cell repertoire, e.g., breast constituents
that are first expressed at puberty (27). Therefore, autoreactive
T cells that are not deleted in the thymus need to be silenced
in the periphery to prevent immune responses to self-tissues.
We would argue that it is essential for DCs to play a role
in the induction of peripheral tolerance. The reasoning is as
follows. Maturing DCs have the capacity to process and
present peptides from dying cells to CD4 and CD8 T lym-
phocytes (28–31). In fact, DCs may be the principal cells
that present antigens from dying cells (“cross presentation”;
see below). In this light, consider what might occur during
influenza infection of the airway (Fig. 1). During infection,
there is extensive death of virus-infected, airway epithelial
cells or “self.” How do DCs focus immunity on the virus,
when they also should be presenting self-antigens from the
infected, apoptotic, airway epithelial cells (29, 32; Fig. 1)?
Because cell death is a feature of many infections, the dan-
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ger of what Ehrlich rightly termed “horror autotoxicus” is
hardly limited to influenza.
Thus, peripheral tolerance to those peptides that can be
processed from dying cells seems critical for preventing au-
toreactivity, but when and how does this occur? It would
be valuable for DCs to induce peripheral tolerance to dying
noninfected tissues, since this would inactivate the key self-
reactive T cells before the DCs are called upon to initiate
immunity to microbial antigens. In effect, peripheral toler-
ance should share with central thymic tolerance the capac-
ity to self-tolerize before foreign antigen exposure and to
use the same APC that will later be called upon to initiate
immunity.
 
Peripheral Tolerance to Tissue Antigens Via Bone
Marrow–derived Cells in Draining Lymph Nodes
 
Precise tools have been developed to study peripheral
tolerance. Neo self-antigens are expressed as transgenes in
peripheral tissues, and then the animal is injected with the
corresponding antigen-reactive, TCR transgenic T cells.
Adler et al. (33) expressed the influenza hemagglutinin (HA)
in many tissues. When HA-reactive CD4
 
1
 
 T cells were in-
jected, the T cells were anergized, and when bone marrow
chimeras were examined, the marrow-derived cells had to
express the MHC that was recognized by the anergized,
HA-reactive, TCR transgenic T cells (33). Anergy did not
develop if only nonhematopoietic tissue cells expressed the
appropriate MHC. In similarly elegant studies, Kurts et al.
(34, 35) expressed OVA sequences in insulin-producing 
 
b
 
cells of pancreatic islets (Fig. 2). The OVA antigen in tissue
cells was again presented to T cells by marrow-derived cells
(34), and the TCR transgenic CD8
 
1
 
 T cells seemed to be
tolerized by deletion after a series of cell divisions (35).
Kurts et al. showed that the tolerizing, marrow-derived
cells were confined to the draining lymph nodes (Fig. 2), i.e.,
the nodes that received afferent lymphatics from the tissue
expressing the OVA antigen (the pancreas or kidney in
their studies). Analogous results have been reported by oth-
ers (36–38).
Somehow then, self-antigens in peripheral tissues are
transferred to marrow-derived cells in a lymph node, and
this can tolerize adult T cells. Although the marrow-derived
cells have yet to be pinpointed, DCs are a likely candidate
since they comprise a link between the peripheral tissues
and the lymph node, the latter being the site where the tol-
erizing self-signals appear to be presented.
 
The Capture of Tissue Cells by DCs
 
Phagocytic inclusions have been described previously in
DCs that traffic from tissues to lymph nodes in afferent
lymph (39–41). Huang et al. now show that these inclu-
sions are apoptotic bodies (23). Furthermore, their new data
indicate that the apoptotic bodies derive from intestinal ep-
ithelium, presumably picked up from epithelial cells under-
going normal cell turnover.
The only comparable description of phagocytic inclu-
sions in DCs in situ is a report involving NK cell–mediated
clearance of allogeneic leukocytes (42). DCs may also take
up apoptotic bodies during negative selection in the thymic
medulla (43), but one cannot visualize this, presumably be-
cause the digestion of apoptotic cells is so rapid (28). Like-
wise, it is difficult to identify macrophages with phagocy-
Figure 1. An illustration of the self-nonself problem
from the perspective of DCs. During influenza infection
of the airway, a site rich in DCs (reference 59), there is
extensive apoptotic death of infected airway epithelial
cells, which the DCs would likely process simulta-
neously with the influenza virus (references 29, 30).
Figure 2. Diagram of the model of Kurts et al. (ref-
erences 34, 35). Self-peptides in tissue cells, here the
insulin-producing b cells of the pancreatic islets, are
presented in a tolerogenic way by bone marrow–
derived cells in the draining pancreatic lymph nodes. 
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tosed dying cells in situ. For example, many developing
thymocytes undergo apoptosis if they fail to be positively
selected. The thymocytes are likely to be scavenged by
macrophages in the cortex, but this is only evident histo-
logically if massive thymocyte death is induced with ste-
roids or irradiation (43).
Therefore, the sighting by Huang et al. (23) of apoptotic
epithelial cells in mesenteric lymph DCs suggests a major
flux of tissue antigens via DCs that are heading to lymph
nodes. Immature DCs or their precursors may always be
trafficking through tissues (44, 45), picking up apoptotic
material from cells undergoing the turnover that is charac-
teristic of most tissues. If the events described by Huang et al.
(23) silence reactivity to the intestinal peptides that are pro-
cessed from dying cells, then DCs maturing during a subse-
quent intestinal infection would only stimulate a response
to foreign antigen, thus alleviating the problem posed in
Fig. 1.
 
Processing of Apoptotic Cells onto MHC Class I and II Products
 
Formation of MHC class I–peptide complexes from an-
tigens in endocytosed dying cells (29, 30) illustrates phe-
nomena termed the “exogenous pathway” and the “cross-
presentation” of antigens. In the exogenous pathway, MHC
class I molecules present peptides derived from endocy-
tosed proteins, rather than newly synthesized (“endog-
enous”) proteins in the cytoplasm. One example of the exog-
enous pathway is cross-presentation, since exogenous peptides
from cells of one MHC, or even xenogeneic MHC, are
presented by DCs of a different MHC.
DCs efficiently carry out the exogenous pathway for
MHC class I. This applies to peptides derived from im-
mune complexes (46), bacteria (47), and apoptotic cells dy-
ing because of viral (29, 30) or bacterial (31) infection. Ro-
driguez et al. have shown that molecules with molecular
masses of 3–20 kD somehow can escape the endocytic sys-
tem of DCs into the cytoplasm (48). They postulate that
the endocytic vacuoles of DCs have a transporter or pore
whereby substrates gain access to TAP molecules in the en-
doplasmic reticulum, followed by presentation on MHC
class I. The recent results from the Bhardwaj and Amig-
orena laboratories also provide evidence that the exoge-
 
nous pathway is expressed much more efficiently in DCs
than in macrophages and B cells (30, 46, 48).
 
Effects of Apoptotic Cells on DC Maturation
 
The paper by Sauter et al. in this issue introduces the
critical events of DC maturation to this topic. The uptake
of apoptotic cells in the steady state must not mature the
DCs if these cells are to induce tolerance rather than im-
munity, and indeed this is what Sauter et al. (24) and Gal-
lucci et al. (49) now report. Immature DCs selectively
carry out phagocytosis of apoptotic cells (28, 30), as is also
the case for the uptake of microbes, latex, and immune
complexes (4, 46, 50). For one thing, relevant phagocytic
receptors are better expressed on immature DCs, e.g., 
 
a
 
V
 
b
 
5
 
integrin for apoptotic bodies and Fc
 
g
 
R for immune com-
plexes (30, 46).
If DCs only take up apoptotic cells when immature (28,
30), if apoptotic cells do not mature the DCs (24), and if
immature DCs are poor stimulators of immunity (1), then
what are the immunological consequences to the carriage
of large numbers of dying somatic cells by DCs in lymph
(23)? Is uptake immunologically “null,” like the clearance
of apoptotic bodies by macrophages, or might peripheral
tolerance ensue?
 
Hypothesis: Immature DCs Phagocytose Tissue Cells Undergoing 
Normal Cell Turnover by Apoptosis; This Leads to Tolerance or 
Regulation of Self-reactive, Adult T Cells in the Draining
Lymph Node
 
In the steady state, i.e., in the absence of inflammation, in-
fection, and necrosis, DCs are always found in afferent
lymph, where they are also called “veiled cells.” Veiled cells
might derive from precursors in the blood (6, 51) including
monocytes (44, 45). The idea is that circulating immature
DCs and monocytes can traffic through tissues, picking up
cells that die by apoptosis (28, 30), and then enter the affer-
ent lymph (Fig. 3). In the steady state, these DCs will not re-
ceive maturation stimuli and therefore will be unable to
stimulate immunity to the self-antigens they have captured.
How might immature DCs induce tolerance to self-anti-
gens in phagocytosed apoptotic cells? One view is that mi-
gratory immature DCs tolerize T cells directly because of a
lack of costimulators (Fig. 3). There are potential difficulties
Figure 3. Pathways whereby DCs might induce pe-
ripheral tolerance to antigens within tissue cells under-
going normal cell turnover by apoptosis. DC precur-
sors traffic through tissues, phagocytose dying cells or
apoptotic bodies, and then enter the lymph. Upon
reaching the lymph node, the DCs tolerize naive, self-
reactive T cells either directly, or indirectly (as dia-
grammed here) after reprocessing by different regula-
tory or tolerogenic DCs in the lymph node. 
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with this idea. For example, we have just found that imma-
ture DCs do not process endocytosed antigens well to form
MHC–peptide complexes (Inaba, K., S. Turley, T. Iyoda, F.
Yamaide, S. Shimoyama, C. Reis e Sousa, R.N. Germain, J.
Mellman, and R.M. Steinman, manuscript submitted for
publication). Therefore, self-reactive T cells would not be
able to recognize their ligand on immature DCs. Also, the
immature DCs may lack the CD40 and TRANCE-R that
sustain DC viability for the 3–4 d needed before T cell toler-
ance becomes evident (35, 37). In contrast, as summarized
above, mature DCs express high levels of MHC–peptide, as
well as the CD40 and TRANCE-R that sustain DC viability
during the interaction with activated T cells (52). Possibly the
migratory immature DCs overcome some of these potential
shortcomings and develop their tolerizing function upon en-
countering T cells or other stimuli after reaching the node.
A second mechanism is that there will be subsets of DCs,
as first proposed by Suss and Shortman (53), that are some-
how specialized to regulate immunity or to induce toler-
ance. Direct evidence for this DC subset remains elusive.
However, the idea is that immature DCs capture apoptotic
bodies peripherally and transfer tissue-derived peptides to
tolerogenic DCs upon reaching the lymph node. We are
intrigued by this possibility because of the information that
migratory DCs in lymph are short lived and appear to be
processed by longer-lived, resident DCs in lymph node
(28). When migratory DCs are injected into mice, the cells
leave the injection site (54), presumably via the afferent
lymph, but 
 
,
 
1% of the injected cells can be recovered 2 d
later in a lymph node according to new data from Josien et
al. (55). The dying, injected DCs are not totally destroyed
by some “big Mac,” but instead can be processed and pre-
sented by DCs in the lymph node (28). The lymph node
DCs can express high levels of MHC–peptide and interest-
ingly, relatively low levels of surface CD86 costimulator
(56). If these lymph node DCs efficiently form MHC–pep-
tide complexes from incoming DCs and their contents, the
former subset may be the best candidate to present self-
antigens from apoptotic cells in a tolerogenic way. We pos-
tulate that there are resident, lymph node DCs which in
the steady state induce tolerance to antigens in apoptotic
bodies carried by migratory lymph DCs (Fig. 3).
Tolerogenic DCs may constitute a separate differentiation
pathway, as suggested by Suss and Shortman (53). Perhaps
these DCs derive from the distinct plasmacytoid precursor
termed DC2 by Liu and colleagues (57, 58). The tolerizing
function of DCs may be quite sophisticated. For example,
tolerance could ensue by deletion or anergy of the self-reac-
tive T cell, as suggested by the work of Adler et al. (33) and
Kurts et al. (34, 35), discussed above. Alternatively, DCs
might expand regulatory T cells. The latter may be needed
for self-antigens at body surfaces like the intestine and airway,
which are unlikely to be devoid of DC maturation stimuli.
 
Conclusion
 
DCs are specialized to control immunity, to trigger im-
mune responses, and also, it appears, to maintain tolerance.
 
These two spheres become intimately linked when one ap-
preciates that cell death often accompanies infection and that
DCs can present self-antigens from dying cells. The matura-
tion of peripheral DCs, which is often triggered by infectious
agents, should allow at least some phagocytosed self-antigens
to become immunogenic. We develop the hypothesis that
immature DCs in the steady state are inducing tolerance to
self-antigens within phagocytosed apoptotic bodies, derived
from the normal turnover of tissues. This occurs well before
the entry of a foreign antigen, so when infection and DC
maturation take place, the immune system can focus on the
foreign peptides that the DCs have processed.
Sauter et al. (24) report that the uptake of apoptotic cells
does not directly mature DCs. Also Huang et al. (23) find
that intestinal lymph DCs normally carry phagocytosed,
apoptotic, intestinal epithelial cells towards the lymph
node, presumably without inducing intestinal autoimmu-
nity. It is known that marrow-derived cells within lymph
nodes can tolerize T cells to peptides synthesized in other
tissues. Thus, DCs may traffic through tissues, pick up apop-
totic cells arising from normal cell turnover, and then, upon
migration to lymph nodes in afferent lymph, silence T cells
to self-antigens in the phagocytosed apoptotic bodies. Tol-
erance to self-antigens in the steady state need not be direct.
It may instead involve transport of apoptotic bodies in short-
lived migratory DCs to longer-lived, tolerizing DCs in the
lymph node. The latter are able in the steady state to form
high levels of MHC–peptide complexes but either lack key
costimulators for immunity or have unique products for in-
ducing tolerance.
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